These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 15848238)

  • 21. Rating scales for dyskinesias in Parkinson's disease.
    Goetz CG
    Mov Disord; 1999; 14 Suppl 1():48-53. PubMed ID: 10493403
    [No Abstract]   [Full Text] [Related]  

  • 22. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias.
    Piccini P; Weeks RA; Brooks DJ
    Ann Neurol; 1997 Nov; 42(5):720-6. PubMed ID: 9392571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
    J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dyskinesia-induced postural instability in Parkinson's disease.
    Armand S; Landis T; Sztajzel R; Burkhard PR
    Parkinsonism Relat Disord; 2009 Jun; 15(5):359-64. PubMed ID: 18851925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis.
    Olanow CW; Gracies JM; Goetz CG; Stoessl AJ; Freeman T; Kordower JH; Godbold J; Obeso JA
    Mov Disord; 2009 Feb; 24(3):336-43. PubMed ID: 19006186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
    Cersósimo MG; Scorticati MC; Micheli FE
    Medicina (B Aires); 2000; 60(3):321-5. PubMed ID: 11050808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Digitised spirography as an evaluation tool for intention tremor in multiple sclerosis.
    Feys P; Helsen W; Prinsmel A; Ilsbroukx S; Wang S; Liu X
    J Neurosci Methods; 2007 Mar; 160(2):309-16. PubMed ID: 17113154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias.
    Morgante F; Espay AJ; Gunraj C; Lang AE; Chen R
    Brain; 2006 Apr; 129(Pt 4):1059-69. PubMed ID: 16476674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
    Kumar N; Van Gerpen JA; Bower JH; Ahlskog JE
    Mov Disord; 2005 Mar; 20(3):342-4. PubMed ID: 15580606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
    Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease.
    Zesiewicz TA; Sullivan KL; Maldonado JL; Tatum WO; Hauser RA
    Mov Disord; 2005 Sep; 20(9):1205-9. PubMed ID: 15954135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new computer method for assessing drawing impairment in Parkinson's disease.
    Westin J; Ghiamati S; Memedi M; Nyholm D; Johansson A; Dougherty M; Groth T
    J Neurosci Methods; 2010 Jun; 190(1):143-8. PubMed ID: 20438759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
    Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR
    Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease.
    Filipović SR; Rothwell JC; van de Warrenburg BP; Bhatia K
    Mov Disord; 2009 Jan; 24(2):246-53. PubMed ID: 18951540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intra- and inter-limb coherency during stance in non-dyskinetic and dyskinetic patients with Parkinson's disease.
    Mann RK; Edwards R; Zhou J; Jog M; Duval C
    Clin Neurol Neurosurg; 2010 Jun; 112(5):392-9. PubMed ID: 20206438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease.
    Vidailhet M; Bonnet AM; Marconi R; Durif F; Agid Y
    Mov Disord; 1999; 14 Suppl 1():13-8. PubMed ID: 10493399
    [No Abstract]   [Full Text] [Related]  

  • 37. Automatic assessment of levodopa-induced dyskinesias in daily life by neural networks.
    Keijsers NL; Horstink MW; Gielen SC
    Mov Disord; 2003 Jan; 18(1):70-80. PubMed ID: 12518302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
    da Silva-Júnior FP; Braga-Neto P; Sueli Monte F; de Bruin VM
    Parkinsonism Relat Disord; 2005 Nov; 11(7):449-52. PubMed ID: 16154788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Grip force abnormalities in de novo Parkinson's disease.
    Fellows SJ; Noth J
    Mov Disord; 2004 May; 19(5):560-5. PubMed ID: 15133821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment.
    Goetz CG; Stebbins GT; Shale HM; Lang AE; Chernik DA; Chmura TA; Ahlskog JE; Dorflinger EE
    Mov Disord; 1994 Jul; 9(4):390-4. PubMed ID: 7969204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.